12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ilaris canakinumab regulatory update

Novartis disclosed in its 4Q10 earnings that it submitted a Type II variation to the European Medicines Agency (EMA) in December to expand the label...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >